Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner

Journal of Cellular Biochemistry

Volumn 108, Issue 1, 2009, Pages 181-194

  Xia, Wenhong ^a   Zhao, Tao ^a   Lv, Jinghuan ^a   Xu, Shan ^a   Shi, Junfeng ^a   Wang, Shui ^a   Han, Xiao ^a,b   Sun, Yujie ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NONE   (China)

Author keywords

Celecoxib; Cyclooxyganes 2; DNA methylation; Drug resistance; P glycoprotein

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; ETOPOSIDE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA METHYLATION; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG UPTAKE; ENZYME INHIBITION; GENE; HUMAN; HUMAN CELL; MDR1 GENE; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; GLYCOPROTEINS; HUMANS; P-GLYCOPROTEIN; PYRAZOLES; SULFONAMIDES; TAMOXIFEN;

EID: 69249114644     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22239     Document Type: Article

References (49)

1. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, Ogier-Denis E. 2002. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 277:27613-27621.
2. Awara WM, El-Sisi AE, El-Sayad ME, Goda AE. 2004. The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: Does celecoxib enhance the anti-tumour activity of doxorubicin? Pharmacol Res 50:487-498.
3. Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF, Hla T. 2004. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 101:591-596.
4. Chuang HC, Kardosh A, Gaffney KJ, Petasis NA, Schonthal AH. 2008. COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol Cancer 7:38.
5. Cornwell MM, Smith DE. 1993. SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J Biol Chem 268:19505-19511.
6. Csiki I, Morrow JD, Sandler A, Shyr Y, Oates J, Williams MK, Dang T, Carbone DP, Johnson DH. 2005. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: A phase II trial of celecoxib and docetaxel. Clin Cancer Res 11:6634-6640.
7. Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA. 2004. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res 10:4062-4067.
8. Davies NM, Gudde TW, de Leeuw MA. 2001. Celecoxib: A new option in the treatment of arthropathies and familial adenomatous polyposis. Expert Opin Pharmacother 2:139-152.
9. de Vries EF, Doorduin J, Vellinga NA, van Waarde A, Dierckx RA, Klein HC. 2008. Can celecoxib affect P-glycoprotein-mediated drug efflux? A micro-PET study. Nucl Med Biol 35:459-466.
10. Ellinger J, Bastian PJ, Jurgan T, Biermann K, Kahl P, Heukamp LC, Wernert N, Muller SC, von Ruecker A. 2008. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 71:161-167.
11. Enokida H, Shiina H, Igawa M, Ogishima T, Kawakami T, Bassett WW, Anast JW, Li LC, Urakami S, Terashima M, Verma M, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. 2004. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res 64:5956-5962.
12. Fantappie O, Masini E, Sardi I, Raimondi L, Bani D, Solazzo M, Vannacci A, Mazzanti R. 2002. The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology 35:843-852.
13. Fantappie O, Solazzo M, Lasagna N, Platini F, Tessitore L, Mazzanti R. 2007. P-glycoprotein mediates celecoxib-induced apoptosis in multiple drugresistant cell lines. Cancer Res 67:4915-4923.
14. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. 2001. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15:2742-2744.
15. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. 2006. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98:736-747.
16. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. 2000. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60:2101-2103.
17. He Q, Luo X, Jin W, Huang Y, Reddy MV, Reddy EP, Sheikh MS. 2008. Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP. Oncogene 27:2656-2660.
18. Huet S, Marie JP, Gualde N, Robert J. 1998. Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: A method validated by the laboratories of the French Drug Resistance Network. Cytometry 34:248-256.
19. Hull MA, Ko SC, Hawcroft G. 2004. Prostaglandin EP receptors: Targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 3:1031-1039.
20. Kang HK, Lee E, Pyo H, Lim SJ. 2005. Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol Cancer Ther 4:1358-1363.
21. Kawamori T, Rao CV, Seibert K, Reddy BS. 1998. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58:409-412.
22. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL. 2005. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 142:157-164.
23. Lai GH, Zhang Z, Sirica AE. 2003. Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Ther 2:265-271.
24. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. 2002. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62:625-631.
25. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. 2000. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 164:820-825.
26. Ludwig JA, Szakacs G, Martin SE, Chu BF, Cardarelli C, Sauna ZE, Caplen NJ, Fales HM, Ambudkar SV, Weinstein JN, Gottesman MM. 2006. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res 66:4808-4815.
27. Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grosch S. 2004. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67:1469-1478.
28. Marie JP, Zittoun R, Sikic BI. 1991. Multidrug resistance (mdr1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity. Blood 78:586-592.
29. Miller B, Patel VA, Sorokin A. 2006. Cyclooxygenase-2 rescues rat mesangial cells from apoptosis induced by adriamycin via upregulation of multidrug resistance protein 1 (P-glycoprotein). J Am Soc Nephrol 17:977-985.
30. Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Furstenberger G. 2002. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci USA 99:12483-12488.
31. Niederberger E, Tegeder I, Vetter G, Schmidtko A, Schmidt H, Euchenhofer C, Brautigam L, Grosch S, Geisslinger G. 2001. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. FASEB J 15:1622-1624.
32. Paulson SK, Zhang JY, Breau AP, Hribar JD, Liu NW, Jessen SM, Lawal YM, Cogburn JN, Gresk CJ, Markos CS, Maziasz TJ, Schoenhard GL, Burton EG. 2000. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metab Dispos 28:514-521.
33. Pereira MA, Tao L, Wang W, Li Y, Umar A, Steele VE, Lubet RA. 2004. Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors. Carcinogenesis 25:1917-1923.
34. Pyrko P, Soriano N, Kardosh A, Liu YT, Uddin J, Petasis NA, Hofman FM, Chen CS, Chen TC, Schonthal AH. 2006. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its noncyclooxygenase-2- inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer 5:19.
35. Qiu YY, Mirkin BL, Dwivedi RS. 2007. MDR1 hypermethylation contributes to the progression of neuroblastoma. Mol Cell Biochem 301:131-135.
36. Ratnasinghe D, Daschner PJ, Anver MR, Kasprzak BH, Taylor PR, Yeh GC, Tangrea JA. 2001. Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? Anticancer Res 21:2141-2147.
37. Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA. 2006. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res 12:3381-3388.
38. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V. 1985. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316:817-819.
39. Rohlff C, Glazer RI. 1998. Regulation of the MDR1 promoter by cyclic AMP-dependent protein kinase and transcription factor Sp1. Int J Oncol 12:383-386.
40. Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC. 2004. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 13:920-927.
41. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. 2006. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 24:2723-2728.
42. Sorokin A. 2004. Cyclooxygenase-2: Potential role in regulation of drug efflux and multidrug resistance phenotype. Curr Pharm Des 10:647-657.
43. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B. 2000. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952.
44. Tegeder I, Pfeilschifter J, Geisslinger G. 2001. Cyclooxygenase- independent actions of cyclooxygenase inhibitors. FASEB J 15:2057-2072.
45. Ueda K, Pastan I, Gottesman MM. 1987. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem 262:17432-17436.
46. Ulrich CM, Bigler J, Potter JD. 2006. Non-steroidal anti-inflammatory drugs for cancer prevention: Promise, perils and pharmacogenetics. Nat Rev Cancer 6:130-140.
47. van Wijngaarden J, van Beek E, van Rossum G, van der Bent C, Hoekman K, van der Pluijm G, van der Pol MA, Broxterman HJ, van Hinsbergh VW, Lowik CW. 2007. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. Eur J Cancer 43:433-442.
48. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, Xie K. 2004. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 64:2030-2038.
49. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN. 2000. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models. Cancer Res 60:6045-6051.